What is Cavion?
Cavion, based in Charlottesville, VA, and Cambridge, MA, is a clinical-stage biotechnology firm focused on modulating T-type calcium channels. The company's therapeutic candidates are designed to address chronic and rare neurological conditions, including essential tremor, Parkinson's disease tremor, neuropathic pain, and epilepsy with absence seizures. By targeting the restoration of natural brain rhythms, Cavion aims to provide novel treatment options for patients suffering from debilitating neurological disorders.
How much funding has Cavion raised?
Cavion has raised a total of $31.5M across 2 funding rounds:
Private Equity
$5M
Series A
$26.5M
Private Equity (2015): $5M, investors not publicly disclosed
Series A (2017): $26.5M led by Novartis Venture Fund, Enso Ventures, and Lilly Ventures
Key Investors in Cavion
Novartis Venture Fund
Novartis Venture Fund is the venture capital arm of Novartis, a global pharmaceutical giant. They focus on investing in innovative companies that align with Novartis's broad therapeutic interests, particularly in areas of significant unmet medical need.
Enso Ventures
Enso Ventures is a venture capital firm that specializes in making selective investments in groundbreaking, high-technology and bio-tech companies, providing capital and expertise to accelerate commercial development.
Lilly Ventures
Lilly Ventures, associated with Eli Lilly and Company, invests in life science innovations, partnering with management teams to realize the potential of their technologies through financial and intellectual resources.
What's next for Cavion?
The recent major strategic investment in Cavion signals a significant milestone, likely enabling the company to advance its pipeline through critical clinical development stages. As a wholly-owned subsidiary of Jazz, Cavion is positioned to leverage broader resources and expertise to accelerate its therapeutic programs. This capital infusion is expected to fuel further research and development, potentially leading to the progression of its T-type calcium channel modulators towards regulatory approval and market entry, addressing unmet needs in the neurological disease landscape.
See full Cavion company page
